Publications by authors named "Samuel Lederman"

Claim this Profile
S
Sustained Efficacy of Oteseconazole in Women with Recurrent Vulvovaginal Candidiasis.
Samuel N Lederman, Ryan Sobel, Jack D Sobel, Stacey B Curelop, Stephen R Brand

J Womens Health (Larchmt)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world comparison of the clinical and economic utility of OVA1 and CA125 in assessing ovarian tumor malignancy risk.
Gerard P Reilly, David A Gregory, Dennis J Scotti, Samuel Lederman, Wade A Neiman

J Comp Eff Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Genevieve Neal-Perry, Antonio Cano, Samuel Lederman, Rossella E Nappi, Nanette Santoro

Obstet Gynecol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Samuel Lederman, Faith D Ottery, Antonio Cano, Nanette Santoro, Marla Shapiro

Lancet· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).
Jane R Schwebke, Ryan Sobel, Janet K Gersten, Steven A Sussman, Samuel N Lederman

Clin Infect Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
Nanette Santoro, Arthur Waldbaum, Samuel Lederman, Robin Kroll, Graeme L Fraser

Menopause· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
Graeme L Fraser, Samuel Lederman, Arthur Waldbaum, Robin Kroll, Nanette Santoro

Menopause· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Denosumab in postmenopausal women with low bone mineral density.
Michael R McClung, E Michael Lewiecki, Stanley B Cohen, Michael A Bolognese, Grattan C Woodson, Samuel N Lederman

N Engl J Med· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens.
Wulf H Utian, Samuel A Lederman, Brenda M Williams, Rhonda Y Vega, William D Koltun

Obstet Gynecol· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis